12:00 AM
Jan 04, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Allovectin-7: Phase III ongoing

For the third time, a DSMB recommended continuation of the single-blind, U.S. Phase III AIMM trial based on a review of safety data. Vical has an SPA from FDA for the study, which is evaluating 2 mg interlesional Allovectin-7 vs....

Read the full 176 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >